A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
2018
2586Background: CRAF is a key mediator of
oncogenic
mitogen-activated protein kinase(MAPK) pathway reactivation following MEK or BRAF inhibition. LXH254 is a BRAF and CRAF inhibitor with antitumor...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
7
Citations
NaN
KQI